Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, September 24, 2024
Lonza announced the signature of a long-term commercial supply agreement for CASGEVY® (exagamglogene autotemcel).
read more
Monday, February 03, 2020
Lonza announced a clinical manufacturing agreement with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.
read more
Lonza announced today the construction of a new small molecule manufacturing complex at its Visp (CH) site.
read more
Wednesday, February 03, 2021
Lonza has expanded its human primary cell offerings with the launch of fully customizable cryopreserved Leukopaks.
read more
Lonza has announced significant investments to expand its mammalian drug substance manufacturing facilities in Visp (CH) and Portsmouth (US).
read more
Tuesday, November 17, 2020
Lonza has announced that it now provides a large selection of high-resolution HLA-typed primary cells spanning all major cell and tissue types.
read more
Monday, November 06, 2017
Lonza Walkersville announced its new offering of Silensomes Human Liver Microsomes products – pooled human liver microsomes for in vitro cytochrome P450 phenotyping.
read more
Friday, November 06, 2020
Lonza inaugurated the first of two manufacturing suites for ADC drug-linker manufacturing at the Visp (CH) site.
read more
Tuesday, February 26, 2019
Lonza announced Richard Ridinger, CEO, has decided to retire from the company after seven years.
read more
Monday, September 28, 2026
Lonza Capsugel has introduced a service to help drugmakers measure nitrite in empty gelatin capsules and assess whether it could contribute to nitrosamine formation in finished medicines.
read more
Tuesday, January 17, 2023
Lonza announced two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering.
read more
Lonza announced it has completed the acquisition of Capsugel from KKR for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion.
read more
Wednesday, March 29, 2023
The new line will support customers with a range of drug product manufacturing needs for both clinical and commercial supply.
read more
Lonza has enhanced its offering for customers in the early phases of their clinical trials by adding a dedicated Early Phase Clinical Manufacturing facility at its Small Molecules site in Bend, Oregon.
read more
Friday, February 17, 2023
Lonza has completed its planned expansion of the bioconjugation facility in Visp (CH). The expansion includes two new manufacturing suites and supporting infrastructure to accommodate a wider range of customers, including companies entering clinical ...
read more